• Startseite
• lx arp1
• CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ

CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ

4.7 (273) · € 19.00 · Auf Lager

Demystifying the Druggability of the MYC Family of Oncogenes

Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib

CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ

Alternative approaches to target Myc for cancer treatment

Alternative approaches to target Myc for cancer treatment

questions and strength and direction of the recommendations

In vitro and in vivo efficacy of the novel oral proteasome

4-Chlorobenzoyl berbamine, a novel berbamine derivative, induces

IJMS, Free Full-Text

CaMKII Gamma antibody (12666-2-AP)

Univariate analysis of progression-free survival (PFS) and overall